Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Prof. Matthew Wood and Dr. Samir El Andaloussi, both of DPAG, have been awarded a new £1m grant from the MRC to study gene therapy for Huntington’s Disease.

Huntington’s is a devastating disorder caused by mutations in a single gene, which result in production of a toxic protein. This protein accumulates in the brain, resulting in the progressive degeneration of nerve and muscle cells leading to death, on average within 25 years of diagnosis.

The Oxford researchers hope to employ a type of naturally occurring cell transport method, called exosomes, to deliver gene therapy directly to the brain. They will test their approach in a mouse model of the disease in the hope of proving that this could be a potential mechanism of delivering human therapy.

Similar stories

Fellowship to Jose Prius Mengual paves the way to new genetic therapy for epilepsy

Congratulations are in order to Dr Jose Prius Mengual who has been awarded an Emerging Leader Fellowship Award from Epilepsy Research UK and the Nucleic Acid Therapy Accelerator (NATA). With this award, Dr Mengual will develop a new genetic therapy to rebalance protein levels in the neurons affected by epilepsy to prevent seizures.